About IGM Biosciences, Inc.
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com.
Imvotamab in Autoimmune and Inflammatory Diseases
Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).
Company Details
- Employees
- 110
- Founded
- -
- Address
- 325 E Middlefield Rd, Mountain View,california 94043,united States
- Phone
- (650) 965-7873
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- igmbio.com
- Keywords
- Autoimmunity, Inflamation, Bispecific, Antibody.
- HQ
- Mountain View, California
Igm Biosciences, Inc. Questions
Igm Biosciences, Inc.'s helpline number is (650) 965-7873
Igm Biosciences, Inc.'s website is igmbio.com
Igm Biosciences, Inc.'s LinkedIn profile is https://www.linkedin.com/company/igm-biosciences
Igm Biosciences, Inc. has
110 employees.
View email and phone details for 110
employees at Igm Biosciences, Inc..
Igm Biosciences, Inc.'s industry is
Biotechnology Research
Igm Biosciences, Inc.'s top competitors are
Hoth Therapeutics, Inc,
Genentech,
Allogene Therapeutics,
Sana Biotechnology, Inc.,
Denali Therapeutics,
Capricor Therapeutics, Inc.,
Sentynl Therapeutics, Inc.,
Kura Oncology, Inc.,
Gilead Sciences,
Atara Biotherapeutics.
Igm Biosciences, Inc.'s support email address is info@igmbio.com
Igm Biosciences, Inc.'s categories are Biotechnology Research
Igm Biosciences, Inc.'s founding year is 2010
